International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. (Q48170931)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

chronic myeloid leukemia

0 references

0 references

quality of life

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Giovanni Caocci

6

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

8

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

12

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

Mirjam A G Sprangers

10

object named as

Mirjam Sprangers

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

Gianantonio Rosti

21

object named as

Gianantonio Rosti

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

Fausto Castagnetti

13

object named as

Fausto Castagnetti

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

Michele Baccarani

2

object named as

Michele Baccarani

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

Massimo Breccia

3

object named as

Massimo Breccia

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

1

object named as

Fabio Efficace

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

Franco Mandelli

22

object named as

Franco Mandelli

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

Susanne Saussele

4

object named as

Susanne Saussele

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

François Guilhot

7

object named as

Francois Guilhot

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

9

object named as

Adel Naeem

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

Annarita Cardoni

16

object named as

Annarita Cardoni

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

Marzia Salvucci

19

object named as

Marzia Salvucci

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

Ourania Nicolatou-Galitis

20

object named as

Ourania Nicolatou-Galitis

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

author name string

Gregory Abel

5

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

Simone Oerlemans

11

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

Felice Bombaci

14

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

Giora Sharf

15

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

Lucien Noens

17

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

Stephan Pallua

18

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

publication date

13 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

Quality of Life Research

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

23

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

3

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

825-836

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy--Leukemia (FACT-Leu) questionnaire

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Educational session: managing chronic myeloid leukemia as a chronic disease

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Measuring the symptom burden associated with the treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11136-013-0523-5

21 January 2018

Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/24026634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

1 reference

https://pubmed.ncbi.nlm.nih.gov/24026634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11136-013-0523-5

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/24026634

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48170931&oldid=2209185330"